It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Endothelial cells express neuropilin 1 (NRP1), endoglin (ENG) and vascular endothelial growth factor receptor 2 (VEGFR2), which regulate VEGF-A-mediated vascular development and angiogenesis. However, the link between complex formation among these receptors with VEGF-A-induced signaling and biology is yet unclear. Here, we quantify surface receptor interactions by IgG-mediated immobilization of one receptor, and fluorescence recovery after photobleaching (FRAP) measurements of the mobility of another coexpressed receptor. We observe stable ENG/NRP1, ENG/VEGFR2, and NRP1/VEGFR2 complexes, which are enhanced by VEGF-A. ENG augments NRP1/VEGFR2 interactions, suggesting formation of tripartite complexes bridged by ENG. Effects on signaling are measured in murine embryonic endothelial cells expressing (MEEC+/+) or lacking (MEEC-/-) ENG, along with NRP1 and/or ENG overexpression or knockdown. We find that optimal VEGF-A-mediated phosphorylation of VEGFR2 and Erk1/2 requires ENG and NRP1. ENG or NRP1 increase VEGF-A-induced sprouting, becoming optimal in cells expressing all three receptors, and both processes are inhibited by a MEK1/2 inhibitor. We propose a model where the maximal potency of VEGF-A involves a tripartite complex where ENG bridges VEGFR2 and NRP1, providing an attractive therapeutic target for modulation of VEGF-A signaling and biological responses.
A mechanistic study provides insight into complex formation between neuropilin-1, endoglin and VEGFR2 as well as the functional consequences of such associations in VEGF-A induced angiogenesis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Zhang, Manqi 3 ; Blobe, Gerard C. 4 ; Henis, Yoav I. 1
1 George S. Wise Faculty of Life Sciences, Tel Aviv University, Department of Neurobiology, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
2 George S. Wise Faculty of Life Sciences, Tel Aviv University, Shmunis School of Biomedicine and Cancer Research, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
3 Duke University Medical Center, Department of Medicine, Durham, USA (GRID:grid.189509.c) (ISNI:0000 0001 0024 1216)
4 Duke University Medical Center, Department of Medicine, Durham, USA (GRID:grid.189509.c) (ISNI:0000 0001 0024 1216); Duke University Medical Center, Department of Pharmacology and Cancer Biology, Durham, USA (GRID:grid.189509.c) (ISNI:0000 0001 0024 1216)




